By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Gen-Probe fell more than 2 percent in Tuesday trade after a report in The Wall Street Journal said that Novartis was no longer "actively pursuing" a deal to acquire the San Diego-based molecular diagnostics firm.

Novartis was believed to be the sole remaining bidder for Gen-Probe after Life Technologies and Thermo Fisher Scientific reportedly backed out of the bidding process.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.